Filing Analysis
Acrivon Therapeutics reported the results of its 2026 Annual Meeting of Stockholders held on June 17, 2026. Key outcomes included the election of two Class I directors, the ratification of PwC as the independent auditor, and the approval of an amended equity incentive plan.
📋 Key Facts
- Stockholders approved the Amended and Restated 2022 Equity Incentive Plan, increasing the share reserve by 3,000,000 shares for a total of 8,606,723 shares.
- The equity plan includes an automatic annual increase (evergreen provision) of 5% of fully diluted shares through 2032.
- Michael Tomsicek and Charles Baum were elected as Class I Directors until the 2029 Annual Meeting.
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Quorum was established with 73.21% of outstanding shares present or represented by proxy.
Acrivon Therapeutics reported its financial results for the first quarter ended March 31, 2026, and provided a general business update. The disclosure was made via a press release furnished as an exhibit to the filing.
📋 Key Facts
- Announced financial results for the quarter ended March 31, 2026, on May 13, 2026.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- The company is an emerging growth company as defined by the SEC.
- The filing includes Exhibit 99.1, which is the press release detailing financial performance.
Acrivon Therapeutics reported its Q4 and full-year 2025 financial results and provided a clinical update on its ACR-368 Phase 2b study. The company is initiating a new registrational-intent arm for endometrial cancer and has successfully completed an exploratory arm involving gemcitabine sensitization.
📋 Key Facts
- Announced financial results for the fourth quarter and full year ended December 31, 2025.
- Initiated Arm 4 of the registrational-intent ACR-368 Phase 2b study for serous type endometrial cancer subjects with ≤2 prior lines of therapy.
- Completed exploratory Arm 2 of the study, which treated biomarker-negative (BM-) subjects with ACR-368 and ultra-low dose gemcitabine (ULDG) sensitization.
- Reported that Arm 2 objectives were achieved, supporting ULDG's role in ACR-368 efficacy for BM- subjects with a favorable tolerability profile.
Acrivon Therapeutics terminated its companion diagnostic agreement with Akoya Biosciences to bring ACR-368 OncoSignature testing in-house. The transition follows the completion of Acrivon's own CLIA-certified laboratory, granting the company full control over its diagnostic development and commercialization rights.
📋 Key Facts
- On February 25, 2026, the company terminated the OncoSignature Companion Diagnostic Agreement with Akoya Biosciences (a Quanterix subsidiary).
- The termination involves no financial payments or penalties from either party.
- Acrivon has established its own internally-owned and operated CLIA-certified laboratory in Watertown, Massachusetts.
- Quanterix will continue to provide testing support during a transition period for the ongoing registrational-intent Phase 2b study.
- Acrivon retains full development and commercialization rights to the proprietary ACR-368 OncoSignature test.
Acrivon Therapeutics hosted a Key Opinion Leader (KOL) panel at the ESGO Congress to discuss interim Phase 2b clinical data for ACR-368. The presentation focused on the drug's registrational-intent trial and its potential to treat endometrial cancer, specifically the serous sub-type.
📋 Key Facts
- The KOL panel took place on February 27, 2026, at the European Society of Gynecological Oncology (ESGO) Congress in Copenhagen.
- Discussion included interim clinical data from the ACR-368 Phase 2b registrational-intent trial.
- The company is targeting unmet patient needs in endometrial cancer, particularly the serous sub-type.
- Presentation slides were filed as Exhibit 99.1.